Eli Lilly's late-stage clinical trial of a monoclonal antibody treatment for COVID-19 has been paused by federal regulators due a safety concern, the company said Tuesday. The treatment was halted due to a safety concern, leading the USA equity market to deepen losses.
Lilly shares were down almost 3 percent amid the news on Tuesday, with the COVID-19 vaccine setback weighing on Wall Street.
MSCI's broadest index of Asia-Pacific shares outside of Japan.MIAPJ0000PUS fell 0.2 percent.
The use of antibodies to treat COVID-19 made headlines in the past week after President Trump said he received an antibody cocktail from Regeneron, and touted it as a "miracle" and a "cure".
Kim Sei-young wins first major by taking Women's PGA title
She got off to a spectacular start on Sunday by holing out a 5-iron approach from 188 yards to card an opening-hole eagle two. Kim matched a tournament record with a 29 on the front nine on Friday and shot 32 for the front nine in the final round.
It was not immediately clear whether the pause would affect other clinical trials that Lilly is running for Covid-19, for example among patients with mild to moderate forms of the disease or as a potential prophylaxis.
Trials of that vaccine resumed in other regions after a brief halt. The BLAZE-1 trial is testing the monotherapy and the combination therapy in patients with early symptoms of Covid-19 who have not been hospitalized.
Monoclonal antibodies are lab-generated versions of one of the human body's main defenses against pathogens.
Just last week, Trump promised to get both Regeneron and Eli Lilly's drug approved "urgently".
Second presidential debate between Trump, Biden officially canceled
Bedingfield argued, "We all agreed on these dates in June and we won't let him try at the last second to rewrite the rules". And the Biden campaign refused . "Why now with less than 24 days to go until the election? " he said.
Lilly didn't disclose any details about the safety concern or how many people are affected.
It is administered intravenously by drip. "It's not at all unusual for unexpected illnesses (to occur) in large studies over their duration", Mammen said in a conference call. The final stage of J&J's trial had started recruiting participants in late September, with a goal of enrolling volunteers across more than 200 United States and global locations.
The Johnson & Johnson Phase 3 trial of its Janssen COVID-19 vaccine candidate involves an anticipated 60,000 adults in multiple countries, testing the safety and efficacy of a single dose versus a placebo. At close of trading, J&J was down 2.3 percent while Lilly was down 2.9 percent.
Lilly serves as the primary sponsor on that trial, collaborating with its co-developer on the LY-CoV555 antibody therapy, Canadian biotech AbCellera Biologics Inc.
NASA Delays SpaceX Crew Dragon Launch to November
But plans for a late October lift-off have been scrubbed in favor of an early-to-mid November launch, NASA announced this week. After launch, Crew Dragon will perform a series of maneuvers culminating with rendezvous and docking with the space station.